Influence of human albumin combined with low-dose heparin on disease condition, serology and placental blood flow of severe preeclampsia patients

摘要

Objective: To study the influence of human albumin combined with low-dose heparin on disease condition, serology and placental blood flow of severe preeclampsia patients. Methods: A total of 78 patients with severe preeclampsia in our hospital between May 2011 and February 2017 were chosen as study subjects, treatment methods were reviewed and all patients were divided into control group (n=37) who underwent low-dose heparin plus conventional treatment and observation group (n=41) who underwent human albumin combined with low-dose heparin plus conventional treatment, both lasting for 7 d. Before and after treatment, mean arterial pressure (MAP) and 24 h urinary protein were measured, serum markers of disease were measured by enzyme-linked immunosorbent assay (ELISA), and umbilical artery hemodynamics were detected by color Doppler ultrasound. Results: Before treatment, there was no significant difference between the two groups in MAP, 24 h urine protein, serum disease-related indexes or umbilical artery hemodynamic indexes. 7 d after treatment, MAP and 24 h urine protein levels in observation group were lower than those in control group; serum disease-related indexes TGF-β1 and VEGF contents in observation group were higher than those in control group whereas VCAM-1 and sFlt-1 contents were lower than those in control group; umbilical artery hemodynamic indexes PI, RI and S/D levels in observation group were lower than those in control group. Conclusion: Human albumin combined with low-dose heparin can optimize the disease condition, promote the angiogenesis of placenta and increase the blood supply of placenta in patients with severe preeclampsia.